流行病学指南对日本子宫颈癌治疗趋势及患者结局的影响:日本妇科肿瘤学会指南评价委员会项目
本研究基于日本妇产科学会肿瘤登记库2000至2012年登记的子宫颈癌病例,分析2007年首版日本妇科肿瘤学会子宫颈癌指南发布对治疗趋势和患者结局的影响,共纳入68,707例。趋势分析显示指南发布可能使新辅助化疗减少、放疗增加,主要在Ⅱ期和Ⅲ期接受初次治疗的患者中;生存分析提示指南引入可能改善Ⅲ期患者的总生存,但全部病例中未观察到显著差异。
要点
- 共登记68,707例子宫颈癌病例,研究期为2000至2012年。
- 指南发布可能使新辅助化疗减少、放疗增加,主要在Ⅱ期和Ⅲ期初次治疗患者中。
- 指南引入可能改善Ⅲ期患者总生存,但全部病例中未见显著差异。
核心结论
- 本研究显示指南发布对临床趋势和患者结局可能存在影响。
- 作为日本子宫颈癌指南的首次评价,需持续评价以进一步理解该指南的意义。
研究设计与样本
- 日本妇科肿瘤学会于2007年发布首版子宫颈癌临床指南,并于2011年和2017年两次修订。
- 研究分析日本妇产科学会组织的肿瘤登记库中2000至2012年登记的子宫颈癌病例,共68,707例。
- 流行病学与临床趋势采用卡方检验及标准化残差分析;2004至2009年登记患者的总生存采用Fine and Gray竞争风险模型分析。
主要发现
- 趋势分析显示,指南发布可能使新辅助化疗减少,同时放疗增加,主要在Ⅱ期和Ⅲ期接受初次治疗的患者中。
- 生存分析提示,指南引入可能改善Ⅲ期子宫颈癌患者的总生存,但全部病例中未观察到显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Japan Society of Gynecologic Oncology published its first clinical guidelines for uterine cervical cancer in 2007 which has been revised twice in 2011 and 2017. The aim of this study was to investigate the influence of the first guideline publication on the therapeutic trend and patient outcome by analyzing uterine cervical cancer cases registered to the cancer registry organized by the Japan Society of Obstetrics and Gynecology. METHODS: Data of uterine cervical cancer cases registered to the cancer registry from 2000 to 2012 were provided. Epidemiological and clinical trend were analyzed by the Chi-squared test with subsequent standardized residual analysis. Overall survival among the patients registered between 2004 and 2009 was analyzed using the Fine and Gray competing risk model. RESULTS: 68,707 cases were registered during the study period. A trend analysis revealed that the guideline publication may have led to a decrease in neoadjuvant chemotherapy in parallel with an increase in radiation therapy mainly in stage II and III patients undergoing primary treatment. A survival analysis indicated that the introduction of the guideline may have improved overall survival among stage III uterine cervical cancer patients, even though a significant difference was not observed in all of the cases. CONCLUSIONS: This study demonstrated the potential influence of the guideline publication on the clinical trend and patient outcome. As this is the first assessment of the guideline for uterine cervical cancer in Japan, continuous evaluation is necessary to further comprehend the significance of this guideline.
引用
- Shigeta S, Shida M, Nagase S, et al. Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project. Gynecol Oncol. 2020. PMID: 32718728. doi:10.1016/j.ygyno.2020.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。